Features of immune senescence in liver transplant recipients with established grafts

William Gelson, Matthew Hoare, Sarah Vowler, Arun Shankar, Paul Gibbs, Arne N. Akbar, Graeme J. M. Alexander – 25 January 2010 – Immune senescence is the normal process whereby the human immune system ages, but becomes less effective. We investigated whether liver transplant recipients have features of immune senescence.

Long‐term efficacy of stent placement for treating inferior vena cava stenosis following liver transplantation

Jae Myeong Lee, Gi‐Young Ko, Kyu‐Bo Sung, Dong Il Gwon, Hyun‐Ki Yoon, Sung‐Gyu Lee – 21 January 2010 – The aims of this study were to evaluate both the efficacy of stent placement for treating inferior vena cava (IVC) stenosis and the patency of hepatic veins (HVs) following IVC stent placement. Fourteen hepatic transplant recipients underwent stent placement to treat IVC stenosis. The median interval between transplantation and stent placement was 32 days. Stents varied from 20‐36 mm in diameter and were 60‐120 mm long.

Pretransplant cryptococcosis and outcome after liver transplantation

Costi D. Sifri, Hsin‐Yun Sun, Thomas V. Cacciarelli, Brian Wispelwey, Timothy L. Pruett, Nina Singh – 21 January 2010 – The posttransplant outcomes and optimal management of patients with end‐stage liver disease who develop cryptococcosis prior to transplantation have not been defined. We discuss these issues in the context of successful liver transplantation and pretransplant cryptococcal disease.

Treatment of chronic hepatitis E in liver transplant recipients with pegylated interferon alpha‐2b

Elizabeth B. Haagsma, Annelies Riezebos‐Brilman, Arie P. van den Berg, Robert J. Porte, Hubert G. M. Niesters – 15 January 2010 – Hepatitis E virus (HEV) infections are known to run a self‐limiting course. Recently, chronic hepatitis E has been described in immunosuppressed patients after solid‐organ transplantation. Besides the general recommendation to lower the immunosuppressive medication in these patients, there is currently no specific treatment.

Dual living donor liver transplantation with ABO‐incompatible and ABO‐compatible grafts to overcome small‐for‐size graft and ABO blood group barrier

Gi‐Won Song, Sung‐Gyu Lee, Shin Hwang, Ki‐Hum Kim, Chul‐Soo Ahn, Deok‐Bog Moon, Tae‐Yong Ha, Seog‐Woon Kwon, Gi‐Young Ko, Kyoung‐Won Kim – 15 January 2010 – ABO blood group compatibility has been regarded as an essential prerequisite for successful adult living donor liver transplantation (LDLT). Novel strategies for overcoming the ABO blood group barrier, however, have markedly improved the results of ABO‐incompatible (ABOi) LDLT.

Subscribe to